Titel

Merkliste
1 Ergebnisse

Phase I study evaluating the Fc-optimized FLT3 antibody FLY..:

Jonas S. Heitmann ; Richard F. Schlenk ; Daniela Dörfel...
https://doi.org/10.1186/s13045-023-01490-w. , 2023

Link: https://doi.org/10.1186/s13045-023-01490-w

RT Journal
T1 <Title>Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease</Title>

UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:eda9171042184c4a8c77ebbdbd743b38&Exemplar=1&LAN=DE
				
A1 Jonas S. Heitmann
A1 Richard F. Schlenk
A1 Daniela Dörfel
A1 Sabine Kayser
A1 Konstanze Döhner
A1 Michael Heuser
A1 Felicitas Thol
A1 Silke Kapp-Schwoerer
A1 Jannik Labrenz
A1 Dominic Edelmann
A1 Melanie Märklin
A1 Wichard Vogel
A1 Wolfgang Bethge
A1 Juliane S. Walz
A1 Ludger Große-Hovest
A1 Martin Steiner
A1 Gundram Jung
A1 Helmut R. Salih
PB BMC
YR 2023
K1 AML
K1 MRD
K1 FLT3
K1 Fc-optimized antibody
K1 Immunotherapy
K1 Diseases of the blood and blood-forming organs
K1 RC633-647.5
K1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens
K1 RC254-282
JF https://doi.org/10.1186/s13045-023-01490-w
LK http://dx.doi.org/https://doi.org/10.1186/s13045-023-01490-w
DO https://doi.org/10.1186/s13045-023-01490-w
SF ELIB - SuUB Bremen

Export

RefWorks (nur Desktop-Version!)
Flow (Zuerst in Flow einloggen, dann importieren)